Dr. Reddy's Laboratories Ltd. closed 7.02% short of its 52-week high of 1,420.20 rupees, which the company achieved on August ...

Dr. Reddy's Laboratories Ltd. closed 9.17% short of its 52-week high of 1,420.20 rupees, which the company reached on August ...

Alvotech (NASDAQ:ALVO) and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a collaboration and license agreement to ...

HSBC upgraded Dr. Reddy’s Laboratories Limited (NYSE:RDY) from Buy to Hold, raising the price target to INR1,445 from ...

LIC’s shareholding in Dr. Reddy’s Laboratories rose from 5.6% at the end of September 2024 to 6.5% by December 2024, and ...

Fintel reports that on June 5, 2025, HSBC upgraded their outlook for Dr. Reddy's Laboratories Limited - Depositary Receipt () ...

Dr. Reddy's Laboratories has partnered with Alvotech to co-develop and commercialize a biosimilar for pembrolizumab (Keytruda ...

Under the agreement signed between the two companies, Alvotech and Dr. Reddy’s will be jointly responsible for developing and ...

As per the terms agreement, Alvotech and Dr Reddy’s will jointly develop and manufacture the biosimilar candidate and share ...

Dr. Reddys shares rose over 4% after announcing a global biosimilar partnership with Alvotech for Keytruda. Q4FY25 profit ...

Alvotech and Dr Reddy's entered into a collaboration and license agreement to co-develop, manufacture and commercialize a ...

Alvotech and Dr. Reddy’s Enter into collaboration to co-develop biosimilar candidate to Keytruda® (pembrolizumab).